ZURAGARD
Peakisopropyl alcohol
NDATOPICALSOLUTION
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ZURAGARD (isopropyl alcohol) is 2 (d 2 ) and serotonin type 2 (5ht 2 ) antagonism. First approved in 2019.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZURAGARD is a topical isopropyl alcohol solution approved in April 2019 for dermatological use. The mechanism involves dopamine D2 and serotonin 5-HT2 antagonism, though the exact clinical indication is not specified in available data. This formulation represents a specialized topical delivery system for a well-established active ingredient.
Peak9.8 years to LOE
Product is at peak lifecycle stage with minimal competitive pressure, suggesting stable but not rapidly expanding team opportunities.
Mechanism of Action
2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZURAGARD roles concentrate in manufacturing, quality, and supply chain functions rather than commercial or medical affairs, reflecting a mature topical product with established market position. Career growth on this product focuses on operational excellence, regulatory compliance, and cost management rather than launch or expansion activities.
Quality Control TechnicianClean & Packaging Technician 1
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.